<DOC>
	<DOCNO>NCT00153985</DOCNO>
	<brief_summary>The purpose study determine treatment reduced-dose busulfex , fludarabine alemtuzumab ( CAMPATH ) follow sten cell infusion allow donor stem cell grow patient hemoglobinopathy bone marrow restore circulate blood count . In addition incidence severity side effect graft vs. host disease ( GVHD ) monitor .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Following Chemotherapy Patients With Hemoglobinopathies</brief_title>
	<detailed_description>- In order undergo transplant procedure , patient admit hospital approximately 10-14 day . - To prepare patient 's bone marrow accept donor stem cell , receive fludarabine busulfex . Fludarabine give intravenously daily 4 day . Busulfex give daily 4 day . - One day patient receive busulfex fludarabine , also give alemtuzumab intravenously daily 5 day . - Three day end chemotherapy , patient receive infusion donor stem cell . - If patient thalassemia , receive subcutaneous injection filgrastim start day one donor stem cell transfusion continue receive filgrastim every day appear donor stem cell accept . If patient sickle cell disease , filgrastim give , - Additional drug give help prevent infection ( i.e . antibiotic ) . - After stem cell infusion patient examine blood test weekly 1 month . Bone marrow biopsy , blood work also perform 1 month , 3 month , 6 month 1 year stem cell infusion . - Patients study 12 month . After study complete progress monitor annual basis .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients sickle cell disease one following : acute chest syndrome require hospitalization ; nonhemorrhagic stroke central nervous system event last long 24 hour ; recurrent casoocclusive pain recurrent priapism ; sickle neuropathy ; bilateral proliferative retinopathy major visual impairment least one eye ; osteonecrosis multiple joint ; transfusion dependence ; vasoocclusive . Patients thalassemia one following : transfusion dependence ; iron overload ; presence 2 alloantibody red cell antigen . Pregnancy Acute hepatitis Cardiac ejection fraction &lt; 30 % Severe renal impairment Severe residual functional neurologic impairment Evidence HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Hemoglobinopathies</keyword>
	<keyword>Sickle cell anemia</keyword>
	<keyword>sickle cell-hemoglobin C disease</keyword>
	<keyword>sickle cell-B-thalassemia</keyword>
	<keyword>transfusion-dependant thalassemia</keyword>
	<keyword>allogeneic transplant</keyword>
	<keyword>nonmyeloablative transplant</keyword>
	<keyword>Stem cell transfusion</keyword>
	<keyword>graft vs. host disease</keyword>
</DOC>